skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Carboranyl amino acids for site specific neutron capture therapy of malignant melanoma

Technical Report ·
OSTI ID:5266146

The single most difficult problem yet to be solved for effective clinical use of boron neutron capture therapy (BNCT) in the United States is the development of highly tumor-selective third generation boron compounds. In this context, the boronated amino acids and peptides would be a significant step toward this goal. Our preliminary in vitro finding that carboranylalanine is a highly potent neutron sensitizer strongly suggests that this amino acid is a most desirable third generation compound, and our development of both chiral and achiral synthesis for its production are a necessary prerequisite for advancement of the field in this area. We further believe that insertion of this amino acid into carefully selected peptides will provide substances able to a target a much wider variety of malignancies than just melanoma. It seems clear that further investigations into this promising field are warranted if BNCT is to achieve clinical acceptability.

Research Organization:
California Univ., San Francisco, CA (United States)
Sponsoring Organization:
USDOE; USDOE, Washington, DC (United States)
DOE Contract Number:
FG03-89ER60873
OSTI ID:
5266146
Report Number(s):
DOE/ER/60873-T2; ON: DE92013811
Country of Publication:
United States
Language:
English